Literature DB >> 18372722

Relative bioavailability of scopolamine dosage forms and interaction with dextroamphetamine.

Jason L Boyd1, Brian Du, Zalman Vaksman, James P Locke, Lakshmi Putcha.   

Abstract

The NASA Reduced Gravity Office (RGO) uses scopolamine (SCOP) alone and in combination with dextoamphetamine (DEX) to treat motion sickness symptoms during DC-9 parabolic flights. The medications are sometimes dispensed as custom dosage forms in gelatin capsules for convenience. Reports of treatment failure during flights by the flight surgeons suggest that these formulations may be less efficacious for the treatment of motion sickness due to unreliable and inadequate bioavailability. We estimated bioavailability of four different oral formulations used by the NASA RGO physicians for the treatment of motion sickness.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18372722

Source DB:  PubMed          Journal:  J Gravit Physiol        ISSN: 1077-9248


  3 in total

Review 1.  Acclimation during space flight: effects on human physiology.

Authors:  David Williams; Andre Kuipers; Chiaki Mukai; Robert Thirsk
Journal:  CMAJ       Date:  2009-06-09       Impact factor: 8.262

Review 2.  Clinically Significant Drug-Drug Interactions with Agents for Attention-Deficit/Hyperactivity Disorder.

Authors:  Georgios Schoretsanitis; Jose de Leon; Chin B Eap; John M Kane; Michael Paulzen
Journal:  CNS Drugs       Date:  2019-12       Impact factor: 5.749

Review 3.  Physiological adaptations affecting drug pharmacokinetics in space: what do we really know? A critical review of the literature.

Authors:  Cinzia Dello Russo; Tiziano Bandiera; Monica Monici; Leonardo Surdo; Vincent Lai Ming Yip; Virginia Wotring; Lucia Morbidelli
Journal:  Br J Pharmacol       Date:  2022-03-15       Impact factor: 9.473

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.